Goto, Emi; Yamaguchi, Toshifumi; Hattori, Nobuhiro; Goto, Masahiro; Nishihara, Masami; Uchiyama, Kazuhisa; Rikitake, Yoshiyuki published the artcile< Safety of Ramucirumab regimen without H1-antihistamine premedication in patients with solid cancers>, Reference of 1492-18-8, the main research area is ramucirumab H1antihistamine solid cancer; H1-antihistamines; Ramucirumab; infusion-related reactions; monoclonal antibodies.
Background/Aim: To prevent infusion-related reactions (IRRs), H1-antihistamines (H1AT) are recommended as a premedication for monoclonal antibodies, such as Ramucirumab (RAM), even though there are H1AT-related side effects, such as drowsiness and dizziness. Here, we investigated the safety of H1AT-free RAM regimens in patients with solid cancer. Patients and Methods: We retrospectively reviewed the patients with solid cancer receiving RAM without H1AT at Osaka Medical College Hospital between 2015 and 2019. Results: Among the 123 registered patients, 58 were identified as eligible. The total number of RAM infusions was 291, and the median number of RAM administration was 4 cycles (range = 1-23 cycles). IRRs were not observed in any patient. Conclusion: Although our data are preliminary and limited, H1AT-free RAM regimens may be a treatment option for cancer patients having a significant risk of developing H1AT-related side effects. Further studies are needed to confirm the safety of H1AT-free RAM regimens.
In Vivo published new progress about Colon neoplasm. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Reference of 1492-18-8.
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts